

26 April 2021

DanCann Pharma A/S: Tetra Bio-Pharma Provides an Update on its U.S. REBORN1 Clinical Trial

COPENHAGEN, Denmark, 26 April 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company") hereby on behalf of Tetra Bio-Pharma Inc. ("Tetra"), announce an update on their U.S. REBORN1 Clinical Trial.

DanCann Pharma signed February 25th a Letter of Intent (LOI) with Canadian Tetra Bio-Pharma Inc. concerning the exclusive distribution of the cannabinoid-based medicines Reduvo™ Adversa® and Qixleef™ in Denmark, Norway, Sweden, Finland, and Germany. This press release is passed on from Tetra's own press release, concerning that Tetra has shipped the investigational new drug, QIXLEEF, to the USA for the initiation of the REBORN1 study. The Company has completed the manufacturing of QIXLEEF and has received the cannabis export permit from Health Canada. REBORN1 will investigate cannabis as an alternative to morphine sulfate immediate release in the management of breakthrough pain. QIXLEEF is a botanical drug product with a "fixed ratio" of THC and CBD and is inhaled through a vaporizer.

- **First clinical study to assess cannabis as an alternative to morphine**
- **Tetra completes manufacturing of QIXLEEF clinical trial drug for REBORN1 trial**
- **Export permit received from Health Canada for immediate shipping to USA**

"We are committed to the fight against the opioid crisis. That is why since the authorization of the clinical trial by the FDA in late January 2021, Tetra has worked hard to prepare QIXLEEF for clinical testing. We are on track to initiate this Phase 2 proof-of-concept trial designed to demonstrate that QIXLEEF can provide pain relief faster than an immediate-release oral morphine." said Dr. Guy Chamberland, CEO and CRO of Tetra Bio-Pharma Inc.

REBORN1 is a 10-week open-label randomized study to evaluate the effect of inhaled QIXLEEF compared to morphine sulfate immediate release (MSIR) to improve fast onset of pain relief of breakthrough cancer pain (BTcP). BTcP is a rapid onset, high intensity, and short duration pain episode, which takes place within stable background pain control. The time to peak intensity of an episode ranges from 3 to 15 minutes with a duration of 30 to 60 minutes. They occur with a frequency of 1.5 to 6 times per day and the majority are moderate to severe in intensity (Portenoy and Hagen 1990; Portenoy et al. 1999; Davies et al. 2011). It significantly affects the quality of life of patients with cancer and their ability to function normally (Zeppetella and Davies 2013).

The Tetra stock (OTCQB: TBPMF) rose Friday (April 23, 2021) + 31.56% at close 3:59 PM (EDT) on top of the update.

SOURCE: Tetra Bio-Pharma

View source version on accesswire.com:

<https://www.accesswire.com/641918/Tetra-Bio-Pharma-Provides-an-Update-on-its-US-REBORN1-Clinical-Trial>

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution company based in Denmark. The company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.

About Tetra Bio-Pharma

Tetra Bio-Pharma (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Our evidence-based scientific approach has enabled us to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing biopharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

For further information, please contact:

Jeppe Krog Rasmussen, CEO
E-mail: jkr@dancann.com
Website: www.dancann.com